Humacyte to Participate at Upcoming Investor Conferences in May
Humacyte to Participate at Upcoming Investor Conferences in May
DURHAM, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Executive Officer, Dale Sander, Chief Financial Officer, and B.J. Scheessele, Chief Commercial Officer, will represent Humacyte at the following conferences in May.
北卡罗来纳州达勒姆，2024年5月13日（GLOBE NEWSWIRE）——临床阶段的生物技术平台公司Humacyte, Inc.（纳斯达克股票代码：HUMA）今天宣布，创始人、总裁兼首席执行官劳拉·尼克拉森医学博士、首席财务官戴尔·桑德和首席B.J. Scheessele 商务官员，将代表Humacyte参加5月的以下会议。
H.C. Wainwright BioConnect Investor Conference at NASDAQ
Format: Fireside Chat and one-on-one investor meetings
Date: Monday, May 20, 2024
Time: 5:00 PM EST
Webcast: https://journey.ct.events/
纳斯达克H.C. Wainwright BioConnect投资者会议
形式：炉边谈话和一对一投资者会议
日期：2024 年 5 月 20 日星期一
时间：美国东部标准时间下午 5:00
网络直播： https://journey.ct.events/
A replay will be available for a limited time following the presentation on the Events & Presentations page within the Investors portion of the Humacyte website.
在Humacyte网站投资者部分的活动和演示页面上进行演示后，将在有限的时间内提供重播。
Benchmark's 4th Annual Healthcare House Call Investor Conference
Format: One-on-one investor meetings
Date: Tuesday and Wednesday May 21-22, 2024
基准测试的 4第四 年度医疗保健公司电话会议投资者会议
形式：一对一投资者会议
日期：2024 年 5 月 21 日至 22 日星期二和星期三
About Humacyte
关于 Humacyte
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Humacyte's initial opportunity, a portfolio of HAVs, is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, AV access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte's 6mm HAV for AV access in hemodialysis was the first product candidate to receive the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte's 6mm HAV for urgent arterial repair following extremity vascular trauma also has received RMAT designation. The HAV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.
Humacyte, Inc.（纳斯达克股票代码：HUMA）正在开发一个颠覆性的生物技术平台，以提供可普遍植入的生物工程人体组织、先进的组织结构和器官系统，旨在改善患者的生活并改变医学实践。该公司开发和制造用于治疗各种疾病、损伤和慢性病的无细胞组织。Humacyte最初的机会是HAV产品组合，目前正在进行针对多种血管应用的后期临床试验，包括血管创伤修复、血液透析的AV通路和外周动脉疾病。冠状动脉旁路移植术、小儿心脏手术、1 型糖尿病治疗以及多种新型细胞和组织应用的临床前开发也在进行中。Humacyte的6mm HAV用于血液透析的AV，是第一款获得美国食品药品管理局再生医学高级疗法（RMAT）称号的候选产品，也获得了美国食品药品管理局的快速通道称号。Humacyte 的 6mm HAV 用于四肢血管创伤后的紧急动脉修复，也获得了 RMAT 称号。HAV 被美国国防部长指定为治疗血管创伤的优先项目。欲了解更多信息，请访问 www.humacyte.com。
Humacyte Investor Contact:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com
investors@humacyte.com
Humacyte 投资者联系人：
乔伊斯·阿莱尔
LifeSci 顾问有限公司
+1-617-435-6602
jallaire@lifesciadvisors.com
investors@humacyte.com
Humacyte Media Contact:
Rich Luchette
Precision Strategies
+1-202-845-3924
rich@precisionstrategies.com
media@humacyte.com
Humacyte 媒体联系人：
Rich Luchette
精准策略
+1-202-845-3924
rich@precisionstrategies.com
media@humacyte.com
Source: Humacyte, Inc
资料来源：Humacyte, Inc
译文内容由第三方软件翻译。